- The trend backdrop is active with a 13-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
IOLCP
NSI
Week ended 07 Aug 2026
Weekly Investor Report
IOL Chemicals and Pharmaceuticals Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
167.9 INR
14.7%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 60.1% above the Trend Line and sits at 89.6% of its 52-week range. The latest completed week returned 14.7%, after a -1.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 59/100. Near-term considerations: volume confirmation is below normal.
Setup score
65
out of 100
Latest Close
167.9 INR
7 Aug 2026
1W Return
14.7%
latest completed week
4W Return
-1.9%
short-term follow-through
12W Return
58.4%
quarterly tape
Trend Breadth
51.9%
27 of 52 weeks active
Volume Ratio
0.7x
vs 13-week average
- 5 reversal markers appear in the recent smart-money tape.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
14.7%
Latest completed week; four-week move -1.9%.
Indicator stack
74/62
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
59/100
27 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 60.1% above the Trend Line and sits at 89.6% of its 52-week range. The latest completed week returned 14.7%, after a -1.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9812-week average 0.81
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.98Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers55 reversal markers
No recent accumulation markers. 5 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -1.9% over four weeks, 58.4% over 12 weeks, and 83.5% over one year. The current trend has remained active for 13 consecutive weeks.
Performance by holding period
Active trend streak13 weeks
Active weeks in one year27
Trend breadth51.9%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.86Latest activity-pressure read.
Pressure change-38.4%Four-week change in activity pressure.
Leadership68.81Latest relative-leadership reading.
RS change-17.5%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength73/100Blend of value, momentum, and quality. Underlying universe rank 28; rank 1 is best.
Value40/100Relative valuation strength. Underlying universe rank 61; rank 1 is best.
Quality62/100Profitability and accounting quality. Underlying universe rank 39; rank 1 is best.
Momentum96/100Medium-term price momentum. Underlying universe rank 5; rank 1 is best.
Growth73/100Revenue and earnings growth. Underlying universe rank 28; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework34/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 35.8x Price divided by trailing earnings.
- Price / sales
- 2.1x Market value relative to trailing revenue.
- EV / EBITDA
- 17.9x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 0.8% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 35.9% Gross profit retained from each unit of revenue.
- Operating margin
- 8.1% Operating profit retained from revenue.
- Free-cash-flow margin
- 1.8% Free cash flow generated from revenue.
- Return on invested capital
- 7.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 11.5% Latest one-year revenue growth.
- EPS growth
- 36.2% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 7/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.6% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.6% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.3x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment59/100
Weighted news tone is neutral across 27 relevant articles.
12 positive · 15 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-6.5%Distance below the 52-week high.
13-week volatility8.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher17 of 269 weeks finished lower.
Best week+19.7%Week of 10 Jul.
Worst week-13.3%Week of 17 Jul.
Latest week+14.7%Week of 7 Aug.
Shape of recent returns
Strong gains11
Modest gains6
Flat weeks0
Modest losses7
Sharp losses2
Recent vol8.2%13-week weekly-return volatility.
Base vol6.9%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew6.7% / -3.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank67 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank53 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape62/100
Trend, activity pressure, participation, and risk combine to a 62/100 tape read.
Indicator analysis83/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.98; 5 reversal markers Factors66/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 37; Small Cap Core rank 52 SVQF34/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1034.0 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment59/100Weighted news tone is neutral across 27 relevant articles.
IOL Chemicals & Pharmaceuticals sets 39th AGM for Sep 2, 2026 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 167.9 INR | 14.7% | 104.8 INR | 86.69 INR | 0.86 | 68.81 | 14.3M | On |
| 31 Jul 2026 | 146.3 INR | -1.9% | 101.8 INR | 86.08 INR | 1.03 | 50.50 | 4.7M | On |
| 24 Jul 2026 | 149.2 INR | 0.6% | 99.69 INR | 85.63 INR | 1.21 | 58.96 | 13.3M | On |
| 17 Jul 2026 | 148.3 INR | -13.3% | 97.39 INR | 85.15 INR | 1.32 | 56.26 | 26.8M | On |
| 10 Jul 2026 | 171.1 INR | 19.7% | 95.16 INR | 84.66 INR | 1.39 | 83.39 | 89.2M | On |
| 3 Jul 2026 | 143.0 INR | 7.0% | 92.19 INR | 84.02 INR | 1.29 | 55.57 | 4.3M | On |
| 26 Jun 2026 | 133.7 INR | 2.6% | 90.20 INR | 83.57 INR | 1.26 | 48.45 | 0 | On |
| 19 Jun 2026 | 130.2 INR | -3.0% | 88.70 INR | 83.23 INR | 1.36 | 46.24 | 1.1M | On |
| 12 Jun 2026 | 134.2 INR | 1.9% | 87.33 INR | 82.92 INR | 1.46 | 54.88 | 1.7M | On |
| 5 Jun 2026 | 131.7 INR | 2.1% | 86.00 INR | 82.61 INR | 1.56 | 55.34 | 2.1M | On |
| 29 May 2026 | 129.0 INR | 8.6% | 84.60 INR | 82.32 INR | 1.56 | 52.71 | 32.9M | On |
| 22 May 2026 | 118.7 INR | 12.1% | 83.34 INR | 82.05 INR | 1.50 | 41.05 | 50.0M | On |
| 15 May 2026 | 105.9 INR | 9.3% | 82.44 INR | 81.84 INR | 1.44 | 27.35 | 41.2M | On |
| 8 May 2026 | 96.89 INR | 2.7% | 82.11 INR | 81.70 INR | 1.39 | 14.73 | 5.8M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.